Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Go back to Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors| Gilead Sciences (NASDAQ: GILD) | Delayed: 124.87 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $124.87 | 52 Week High | $108.63 | |||
| Open | $124.87 | 52 Week Low | $71.39 | |||
| Day High | $124.87 | P/E | 68.99 | |||
| Day Low | $124.87 | EPS | $1.81 | |||
| Volume | 6,960 | |||||
